The Japanese Society of Nephrology. Questionnaire survey on renal injury associated with Beni Koji Choleste Help (Interim Report). https://jsn.or.jp/medic/newstopics/formember/2-10.php. Accessed 2025 Feb 21

Shinzawa M, et al. A nationwide questionnaire study evaluated kidney injury associated with Beni-koji tablets in Japan. Kidney Int. 2024. https://doi.org/10.1016/j.kint.2024.11.027.

PubMed  Google Scholar 

Kashoor I, et al. Proximal renal tubular acidosis with and without Fanconi syndrome. Kidney Res Clin Pract. 2019;38(3):267–81.

PubMed  PubMed Central  Google Scholar 

Lovisa S, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015;21:998–1009.

CAS  PubMed  PubMed Central  Google Scholar 

Kobayashi Pharmaceutical Co., Ltd. Request to discontinue use of red yeast rice-related products and notice of voluntary recall (2nd report). https://www.kobayashi.co.jp/info/20240325/. Accessed 2025 Feb 21

Yoshikawa Y, et al. Fanconi syndrome and renal tubular necrosis in patients following ingestion of potentially contaminated red yeast rice supplement: Two case reports. Physiol Rev. 2024;12: e70049.

Google Scholar 

Takeuchi K, et al. Renal impairment of proximal tubular injury caused by red yeast rice supplement: reports of 2 cases. Case Rep Nephrol Dial. 2024;14:128–37.

PubMed  PubMed Central  Google Scholar 

Miyazaki R, et al. Acute kidney tubular injury after ingestion of red yeast rice supplement. Clin Kidney J. 2024;17:sfae151.

PubMed  PubMed Central  Google Scholar 

Oda K, et al. A case of kidney injury and Fanconi syndrome while taking multiple supplements, including Red Yeast Rice Cholesterol Help. CEN Case Rep. 2025;14:47–51.

PubMed  Google Scholar 

Kawai Y, et al. A case of Fanconi syndrome that developed following a year of consumption of a red yeast rice supplement. CEN Case Rep. 2025;14:95–102.

PubMed  Google Scholar 

Maiguma M, et al. Successful treatment of acute tubulointerstitial nephritis probably due to Benikoji CholesteHel®, a supplement containing red yeast rice. CEN Case Rep. 2025;14:24–8.

PubMed  Google Scholar 

Katayama Y, et al. Recurrent acute kidney injury with Fanconi syndrome related to red yeast rice supplement. CEN Case Rep. 2024. https://doi.org/10.1007/s13730-024-00926-7.

PubMed  PubMed Central  Google Scholar 

Koshida T, et al. Renal injuries induced by supplements containing red yeast rice. Intern Med. 2024. https://doi.org/10.2169/internalmedicine.4094-24.

PubMed  Google Scholar 

Murata Y, et al. Certain red yeast rice supplements in japan cause acute tubulointerstitial injury. Kidney Int Rep. 2024;9:2824–8.

PubMed  PubMed Central  Google Scholar 

Uchiyama K, et al. Acute kidney injury associated with red yeast rice (beni-koji) supplement: a report of two cases. Kidney Med. 2024;6: 100908.

PubMed  PubMed Central  Google Scholar 

Chikasue A, et al. Three cases of red yeast rice-containing supplement-induced acute kidney injury and Fanconi syndrome. Am J Kidney Dis. 2024. https://doi.org/10.1053/j.ajkd.2024.08.007.

PubMed  Google Scholar 

Abe M, et al. Element analysis applied to investigate acute kidney injury induced by red yeast rice supplement. Med Mol Morphol. 2025;58:53–61.

PubMed  Google Scholar 

Iwamura N, et al. Subclinical acute tubular necrosis potentially associated with red yeast rice consumption unexpectedly detected in a patient with membranous nephropathy. CEN Case Rep. 2024. https://doi.org/10.1007/s13730-024-00946-3.

PubMed  PubMed Central  Google Scholar 

Habuka M, et al. Fanconi syndrome with acute proximal tubular injury induced by a dietary supplement containing beni-koji: a case series report. BMC Nephrol. 2024;24:446.

Google Scholar 

Perazella MA, et al. Drug-induced acute kidney injury. Clin J Am Soc Nephrol. 2022;17:1220–33.

CAS  PubMed  PubMed Central  Google Scholar 

Poulsen SB, et al. Sodium–glucose cotransport. Curr Opin Nephrol Hypertens. 2015;24:463–9.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94:524–35.

CAS  PubMed  Google Scholar 

Anan G, et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res. 2022;186: 106524.

CAS  PubMed  Google Scholar 

Endo A, et al. Sodium glucose cotransporter 2 inhibitor suppresses renal injury in rats with renal congestion. Hypertens Res. 2024;47:33–45.

CAS  PubMed  Google Scholar 

Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–70.

CAS  PubMed  Google Scholar 

Dobyan DC, et al. Mechanism of cis-platinum nephrotoxicity: II morphologic observations. J Pharmacol Exp Ther. 1980;213:551–6.

CAS  PubMed  Google Scholar 

Rieg T, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Ren Physiol. 2014;306:F188–93.

CAS  Google Scholar 

Fanconi G, Bickel H. Die chronische Aminoacidurie (Amino säurediabetes oder nephrotisch-glukosurischer Zwergwuchs) bei der Glykogenose und der Cystinkrankheit. Helv Paediatr Acta. 1949;4:359–96.

CAS  PubMed  Google Scholar